CANONSBURG (dpa-AFX) - Swedish drugmaker Meda AB's (MDABF.PK, MDABY.PK) board made a statement according to the Securities Markets Act and/or the Financial Instruments Trading act. The board confirmed being contacted by Generic drugmaker Mylan, Inc. (MYL) relating to an indicative proposal to combine the two businesses. The board has convened and has decided to reject the proposal.
Meda said that all continued talks between Meda and Mylan were terminated without further actions.
Copyright RTT News/dpa-AFX